- 英文名称N-(5-(4-(3,3-Dimethylazetidine-1-Carbonyl)Phenyl)-[1,2,4]Triazolo[1,5-A]Pyridin-2-yl)Cyclopropanecarboxamide
- 中文名称索西替尼
- IUPAC名称N-(5-(4-(3,3-dimethylazetidine-1-carbonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
- 其它别名Solcitinib; N-(5-(4-(3,3-Dimethylazetidine-1-Carbonyl)Phenyl)-[1,2,4]Triazolo[1,5-A]Pyridin-2-yl)Cyclopropanecarboxamide; N-[5-[4-(3,3-Dimethylazeti
- CAS编号1206163-45-2
- MFCD编号:MFCD26960569
- FDA UNII编号:3V7GQ1260K
- 分子式:C22H23N5O2分子量:389.46
- 产品CID: 275048
- 产品分类生物化工 → 生化试剂 → 激动剂抑制剂
📜3,3-二甲基氮杂丁烷盐酸盐,4-[2-(Cyclopropanecarbonylamino)-[1,2,4]Triazolo[1,5-A]Pyridin-5-Yl]Benzoic Acid置于3,3-二甲基氮杂丁烷盐酸盐体系中,化学反应生成Solcitinib抑制剂
参考文献:Compound Useful For The Treatment Of Degenerative And Inflammatory Diseases
标题:Compound Useful For The Treatment Of Degenerative And Inflammatory Diseases
摘要:本发明披露了一种化合物,其化学式如下所示:该化合物可以制备为药物组合物,并可用于哺乳动物,包括人类的预防和治疗多种疾病,例如但不限于炎症性疾病,自身免疫疾病,增生性疾病,移植排斥反应,涉及软骨周转障碍的疾病,先天性软骨畸形和/或与il6高分泌相关的疾病.
海关参考信息
- 2912110000-甲醛
2912120000-乙醛
2912210000-苯甲醛
2924191000-二甲基甲酰胺 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-10906888-B2
优先权日:2016-07-14
标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
发明人:CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:US-10308615-B2
优先权日:2015-05-29
标 题:Heterocyclic compounds as inhibitors of Vanin-1 enzyme
发明人:CASIMIRO-GARCIA AGUSTIN; CONDON JEFFREY SCOTT; FLICK ANDREW CHRISTOPHER; GOPALSAMY ARIAMALA; KIRINCICH STEVEN J; MATHIAS JOHN PAUL; STROBACH JOSEPH WALTER; XIANG JASON SHAOYUN; XING LI HUANG; WANG XIAOLUN
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:US-2018230127-A1
优先权日:2015-08-13
标题 :Bicyclic-Fused Heteroaryl Or Aryl Compounds
发明人:ANDERSON DAVID RANDOLPH; CURRAN KEVIN JOSEPH; GAVRIN LORI KRIM; GOLDBERG JOEL ADAM; LEE ARTHUR; LOWE MICHAEL DENNIS; PATNY AKSHAY; PIERCE BETSY SUSAN; SAIAH EDDINE; TRZUPEK JOHN DAVID
权利人:PFIZER
摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of Interleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.
专利号:US-10316018-B2
优先权日:2015-08-27
标题 :Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
发明人:LEE KATHERINE LIN; ALLAIS CHRISTOPHE PHILIPPE; DEHNHARDT CHRISTOPH MARTIN; GAVRIN LORI KRIM; HAN SEUNGIL; HEPWORTH DAVID; LEE ARTHUR; LOVERING FRANK ELDRIDGE; MATHIAS JOHN PAUL; OWEN DAFYDD RHYS; PAPAIOANNOU NIKOLAOS; SAIAH EDDINE; STROHBACH JOSEPH WALTER; TRZUPEK JOHN DAVID; WRIGHT STEPHEN WAYNE; ZAPF CHRISTOPH WOLFGANG
权利人:PFIZER
摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.